Mid Atlantic Gynecologic Oncology and Pelvic Surgery Associates

Appointments (571) 308-1830

Research

Current research efforts are being conducted in collaboration with the National Cancer Institute, the Gynecologic Oncology Group and various industry sponsored protocols to offer our patients the opportunity to participate in cutting edge research. Our research protocols include first line treatment for those patients newly diagnosed with gynecologic malignancies as well as trials for those diagnosed with recurrent or progressive disease. Currently available clinical trials are geared towards ovarian, endometrial and cervical carcinomas.

Each protocol offers patients standard of care treatment along with investigational products that have shown promise in the treatment of cancer. PARP inhibitors, HER2 pathway blockers, anti-VEGF and investigational chemotherapies are being utilized. A Phase I vaccine trial in advanced epithelial and ovarian cancer is also being launched. Tissue acquisition at the time of a patient’s initial surgery is another area of research that may offer benefit to the patient by offering specific treatment tailored to the genetic typing of the tumor. This tissue can be sent for chemotherapy sensitivity and/or molecular profiling in an effort to help individualize therapy.

Current Protocols

Research   Protocols

Indication

Stage

Study   Name

Study Title

Recurrent Ovarian I-IV Yondelis
A Randomized, Open-Label Study Comparing the Combination of YONDELIS®  and
DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of
Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Recurrent Ovarian  with low CA 125 I-IV Morab  011 A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb-003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer
Persistent or recurrent Ovarian I-IV NRG - 003 Phase II Randomized Trial of Nivolumab with or without Ipilimumab in Patients with Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Persistent or recurrent Cervical I-IV NRG - 002 A Phase II Evaluation of Nivolumab, a Fully Human Antibody against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Newly diagnosed Ovarian III-IV Parp Inhibitor A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Leiomyoscarcoma I-IV LMS
A PHASE III RANDOMIZED TRIAL OF GEMCITABINE PLUS DOCETAXEL FOLLOWED BY DOXORUBICIN VERSUS OBSERVATION FOR UTERUS-LIMITED, HIGH-GRADE UTERINE
LEIOMYOSARCOMA
All I-IV Caris A registry of the Target Now test results(biomarker expressions patterns) for evaluation of correlation with clinical outcomes for cancer patients.
All I-IV TDAN Tissue and Data Acquisition for the study of gynecologic disease

 

 

Bookmark and Share

In This Section